Sentences with phrase «most drug companies»

«Most drug companies will say, «My drug is on the market and I'm not going to play with that.

Most drug companies seeking to apply the wealth of data on the human genome to the hunt for new drugs have turned to specialized start - up companies for help (Science, 7 February 1997, p. 767).

Not exact matches

The company's $ 150 million settlement agreement was the largest and most severe of its kind involving a drug wholesaler, or any member of the pharmaceutical supply chain over violations of the Controlled Substances Act.

On average, the 30 large and small pharmaceutical and biotech companies IDEA Pharma examined got just 11 % of their 2017 revenue from drugs developed within the past five years, says Mike Rea, the firm's CEO and one of the most insightful people I've met — no exaggeration — when it comes to pinpointing innovation choke points in the drug industry.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

«Many drug companies are lining their pockets at the expense of some of the most vulnerable families in our nation,» Rep. Elijah Cummings (D - Maryland) wrote in a statement accompanying the memos.

Many drug company executives, including the CEOs of Pfizer and Allergan, were asked about the prospect of working with Amazon on their most recent quarterly earnings conference calls.

Most national companies employing more than 20,000 people keep their prescription drug benefits separate from medical coverage.

By buying the company outright it will now get access to Ablynx's most promising asset, the experimental drug caplacizumab for treating the rare bleeding disorder acquired thrombotic thrombocytopenic purpura.

FORTUNE — One of America's most far - seeing companies, Vertex Pharmaceuticals, the biopharmaceutical startup so memorably chronicled in journalist Barry Werth's classic book, The Billion Dollar Molecule: The Quest for the Perfect Drug, is back.

ASH 2016 has been one of the most anticipated scientific conventions of the year, with companies like Novartis, Kite, and Juno presenting critical new data about a next - gen set of drugs that are being tested in numerous blood cancers.

Yes, the model that most major drug companies are hoping to emulate these days isn't Pfizer (No. 51 on this year's Fortune 500), but rather Bristol - Myers Squibb, No. 176 — which is down from No. 158 in 2013 and a rank of No. 134 the year before.

Early in the decade the company had been dogged by R&D failures, most notably of Vanlev, a high - profile hypertension drug that had been hailed as a can't - miss blockbuster but then fell short of even getting FDA approval.

The field employs 63,000, most of whom work for clinics, drug companies or Health Canada.

Acthar reimbursements have been severely restricted by most large pharmaceutical companies and Tricare has discontinued reimbursements for this drug.

That's an even rarer feat for a generic drug maker such as Mylan, which makes most of its revenue not on brand - name drugs, but on cheaper, equivalent versions of other companies» branded medications.

A thought - provoking discussion on some of the most innovative solutions around drug pricing and the companies pioneering a new way forward.

The most extreme valuations include mass retailers such as Wal - Mart, Target, Home Depot, Best Buy, Kohls, and Lowe's, and large drug and healthcare companies such as Amgen, Abbott Labs, Baxter, American Home Products, Forest Labs, Johnson & Johnson, Medtronic, Stryker, United Healthcare, and Tenet.

The stock prices of most drug related companies have been suppressed a bit recently as a result of politicians voicing their opinions about high drug prices.

** A message from the Coalition for Affordable Prescription Drugs (CAPD): Prescription drugs are often critically important to seniors» health, and yet drug companies continue to increase prices for the very drugs they rely on Drugs (CAPD): Prescription drugs are often critically important to seniors» health, and yet drug companies continue to increase prices for the very drugs they rely on drugs are often critically important to seniors» health, and yet drug companies continue to increase prices for the very drugs they rely on drugs they rely on most.

Conservative foundations, multinational oil companies and a prescription drug maker were the most frequent sponsors of more than 100 expense - paid educational seminars attended by federal judges over a 4 1/2 - year period, according to a Center for Public Integrity investigation.

ICCR encourages pharma companies to share patents for their life - saving HIV drug formulations through the Medicines Patent Pool as a way to make them more affordable and available where they are needed most.

It was a far bigger credit than most companies start off with, and Chainalysis smartly ran with it, signing up customers like the Federal Bureau of Investigation, the Drug Enforcement Administration, the Internal Revenue Service and Europol to help them catch criminals.

Insurance companies, she said, would most likely receive discounts to make the drug cost less than $ 800.

This premium was the most ever for a medical drug acquisition greater than $ 500 million, and represents the length an acquirer will go to buy a company with a novel HCV fighter.

Forecasting Sales Revenue Forecasting the sales revenue from each of a biotech company's drugs is probably the most important estimate you can make about future cash flows, but it can also be the most difficult.

In fact most of us would be trying to scratch out a living on a farm with no modern equipment, hoping for enough rain to produce food for the next year, and dying at 35 yrs old from diseases now cured by drug companies.

The fact is that we have whole industries employing the most advanced scientific and psychological skills to promote institutionalized deceit, not only the advertising and public relations industry, but manufacturers who rely on deceptive packaging and planned obsolescence, and the drug companies who promote drugs before they know what the side effects may be.

Most recently, Vermont passed legislation that will require food companies including Campbell to label products regulated by the Food and Drug Administration (FDA) that may contain ingredients made from GMO crops.

Hospitals and drug companies / CDC feed into this fear with carefully sculpted and fear - promoting statements like: «GBS is the most common infectious cause of mortality.»

While drug companies would love you to believe that their prenatal vitamin is the only thing that will really work, most prenatal vitamins will work for most women, with a few exceptions.

In his role as researcher, he developed a potential drug to treat different types of immune diseases and was able to accompany the molecule through the next stages?something most scientists at pharmaceutical companies are not able to do.

Using the sensor, drug companies can screen individual drug compounds in minutes rather than months, determining which are most effective.

The most promising hits become leads, or compounds that a company pursues as potential drugs.

Several biotech companies — most prominently Geron, which first made a name for itself in telomere research — are working to develop anticancer drugs that would work by deactivating telomerase.

The punishment, imposed in August but only made public today, is apparently the most severe reaction by NIH so far to a Senate investigation of NIH - funded researchers who may have failed to report all of their income from drug companies.

An American who buys golf clubs abroad and doesn't want to declare them can send them via a company that packs them in a shipping container, which then slips them into port without ever being seen by customs agents; the ability of drug dealers to bypass even the most elaborate border controls is a well - known problem.

The plan is to predict very early which drugs are likely to succeed and which are not, and promote the winners rapidly to larger (phase III) trials, which most likely would be run by private companies, without data sharing.

Most of the increase — $ 601 million — would come from user fees charged to drug, device, tobacco, and other companies regulated by FDA, which have supplied FDA with billions of dollars in recent years.

Most smart drugs originated in the research and development laboratories of major drugs companies.

The most important change occurring in the industry is a shift away from the traditional «big pharma» model for drug development, in which research and development are concentrated inside such companies as Pfizer, Merck, and AstraZeneca.

The company aims to use CRISPR gene - editing to craft RNA therapeutics that can be delivered into the central nervous system — clearly a daunting task for most drug makers.

For instance, pharmaceutical companies will most likely continue to generate more lucrative cures for hypertension and high cholesterol, even though existing drugs work well, and ignore other disorders that lack effective drugs.

Most of the increase — $ 601 million — would come from user fees charged to the drug, device, tobacco, and other companies regulated by FDA, which have supplied FDA with billions of dollars in recent years.

Pharmaceutical companies, by contrast, focus most of their efforts at the other end of the drug development pipeline, moving potential drug compounds through human clinical trials into the market.

He says HGS was getting «diminishing returns» from its investment in TIGR since Venter had steered his outfit into sequencing organisms of little medical importance, and into human genome sequencing, also of limited value for a company like HGS that is interested in genes as drug targets (not untranslated DNA that makes up most of the genome).

That's part of the reason that most drugs that work in animals don't work in people — only 11 % of oncology compounds that show promise in mice are ever approved for humans — despite billions of dollars spent by pharmaceutical and biotech companies.

«Most young people with Friedreich's develop severe heart problems and are wheelchair - bound, but the disease is so rare that few drug companies invest in it.»

The companies will use the Clinical Genome Miner ™, which combines genealogical, genotypic and disease data, to develop more detailed understanding of the role of Merck targets in the human biology of obesity, and to establish which targets offer the most promising avenues for the development of new drugs.